by Sharon Rondeau (Feb. 4, 2022) — On January 29, 2022, The Post & Email published a response received from a spokesman for the U.S. Food and Drug Administration (FDA) regarding the abrupt withdrawal of two monoclonal antibody products used to combat COVID-19 in higher-risk individuals as well as the safety and efficacy of the […]
